Therapeutic Outcomes and Biomarker Potential of CDKL3 of Neoadjuvant Chemotherapy in Patients With Stage IIIC Versus Stage IV Epithelial Ovarian Cancer From the Tempus Database, we retrospectively ...
This study was conducted following the methodological guidance provided by the Joanna Briggs Institute for scoping reviews and is reported in accordance with the PRISMA-ScR (Preferred Reporting Items ...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, the leader in precision-engineered cell mimic technologies, today announced the launch of TruCytes™ Potency, a new class of biomarker cell ...
The Cyto-Mine Chroma platform uses fluorescence-based assays in picodroplets to select single cells based on secreted, surface, and/or intracellular markers. Aided by the new multiplexing capability ...
You are free to share (copy and redistribute) this article in any medium or format and to adapt (remix, transform, and build upon) the material for any purpose, even commercially within the parameters ...
Despite scoring a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about its own longevity, cutting funding for two preclinical programs and evaluating strategic ...
A bioprocessing research and training institute in Ireland has successfully tested two new techniques for noninvasive monitoring of cell viability. The National Institute for Bioprocessing Research ...
Drug developers know well the analytical obstacles associated with cell therapies (CTs). Human cells’ large size and biochemical complexity present considerable difficulties for characterization and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback